Table 1.

Summary of cell lines and PDX models with their BRAF and TP53 mutational status

Cancer type	Cell line/PDX	Name	BRAF	TP53
PTC	Cell line	TPC-1	WT	WT
	Cell line	K2	V600E	WT
	Cell line	BCPAP	V600E	D259Y
	Cell line	MDA-T85	V600E	WT
PDTC	Cell line	MDA-T192	WT	WT
ATC	Cell line	MDA-T178	WT	WT
	Cell line	U-Hth83	WT	Y236C and P153fs
	Cell line	Hth7	WT	G245S
	Cell line	MDA-T187	V600E	K132N
	Cell line	SW1736	V600E	No expression, Q192a
	Cell line	Hth104	V600E	No expression
	Cell line	8505C	V600E	R248G
	PDX	MDA-ATC1	V600E	K132N
	PDX	MDA-ATC5	WT	WT

The mutation status of BRAF and TP53 was determined by whole exome sequencing, Sequenom, or Sanger sequencing. The expression of TP53 in Hth104 cells was determined by Western blot analysis after failed Sanger sequencing. MDA-ATC1 was generated from the same patient who gave rise to MDA-T187 cell line and carrying the same BRAF and TP53 mutations as determined by whole-exome sequencing.

Abbreviations: ATC, anaplastic thyroid carcinoma; PDTC, poorly differentiated thyroid carcinoma, PDX, patient-derived xenograft; PTC, papillary thyroid carcinoma; WT, wild-type.

^a Nonsense mutation.